Microbiome-Targeted Therapeutics in Immunology

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.

Scope

GlobalData’s Microbiome-Targeted Therapeutics in Immunology combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology.

Components of the report include:

• Overview of the Gut and Skin Microbiome – microbial dysbiosis by indication

• Epidemiology Overview – prevalent or diagnosed prevalent cases by indication for the 16MM

• Pipeline Assessment—promising late-stage products and early-stage pipeline by indication

• Key Players – leading industry companies by indication

• Clinical Trials Mapping and Design — trial breakdown by phase/indication and trial design by indication

• Fecal Microbiota Transplants—opportunities and challenges for gastrointestinal indications

• Pricing, Reimbursement and Regulatory Strategy – US payer perspective on late-stage therapies

• Market Outlook — market potential estimation of late-stage therapies and key launch dates

Reasons to Buy

Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Gain insights to help plan and design your clinical trials.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Identify key pricing and reimbursement strategies.

Qu Biologics
Synthetic Biologics
4D Pharma
Enterome Bioscience
Second Genome
Seres Therapeutics
Rebiotix
Intrexon
Vedanta Biosciences
AOBiome
Matrisys Bioscience
SFA Therapeutics

Table of Contents

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insight on Microbiome Competitive Landscape

3 Overview of the Gut and Skin Microbiome

3.1 Microbiome of the Skin

3.2 Microbiome in Atopic Dermatitis

3.3 Microbiome in Acne

3.4 Microbiome in Psoriasis

3.5 Microbiome of the Gut

3.6 Microbiome in Inflammatory Bowel Disease

3.7 Microbiome in Irritable Bowel Syndrome

4 Epidemiology Analysis

4.1 Epidemiology Analysis – Acne Vulgaris

4.2 Epidemiology Analysis – Atopic Dermatitis

4.3 Epidemiology Analysis – Psoriasis

4.4 Epidemiology Analysis – Crohn’s Disease

4.5 Epidemiology Analysis – Ulcerative Colitis

4.6 Epidemiology Analysis – Irritable Bowel Syndrome

5 Pipeline Assessment

5.1 Overview of the Development of Pipeline Therapies

5.2 Pipeline Assessment – The Gut Microbiome

5.3 Qu Biologics’ QBECO-SSI

5.4 Synthetic Biologics’ SYN-010

5.5 Pipeline Assessment – The Skin Microbiome

5.6 AOBiome’s B-244

5.7 Matrisys Bioscience’s MSB-01

6. Key Players

6.1 Key Players – Companies Targeting the Microbiome

6.2 Analysis of Company Portfolio Gap – Gut Microbiome

6.3 Analysis of Company Portfolio Gap – Skin Microbiome

7 Clinical Trial Mapping and Design

7.1 Clinical Trial Mapping and Design – Gut Microbiome

7.2 Clinical Trial Mapping and Design – Skin Microbiome

8 Fecal Microbiota Transplants

8.1 Is Fecal Microbiota Transplant a Viable Option?

8.2 Clinical Trial Mapping and Design

9 Pricing, Reimbursement, and Regulatory Strategy

9.1 US Strategies for Gastrointestinal Indications

9.2 Payers Perspective on QBECO-SSI

9.3 Payers Perspective on SYN-010

9.4 US Strategies for Dermatology Indications

9.5 Payers Perspective on B-244

9.6 Payers Perspective on MSB-01

10 Market Outlook

10.1 Market Outlook for AOBiome’s B-244

10.2 Market Outlook for Synthetic Biologics’ SYN-010

10.3 Market Outlook for Qu Biologics’ QBECO-SSI

10.4 Key Launch Dates for Pipeline Therapies

11 Appendix

11.1 Sources

11.2 Methodology

11.3 Primary Research

11.4 About the Authors

11.5 About GlobalData

11.6 Contact Us

11.7 Disclaimer

Frequently asked questions

Microbiome-Targeted Therapeutics in Immunology thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Microbiome-Targeted Therapeutics in Immunology was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Microbiome-Targeted Therapeutics in Immunology in real time.

  • Access a live Microbiome-Targeted Therapeutics in Immunology dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.